Picture loading failed.

Anti-Ganglioside GD2 therapeutic antibody (Pre-made Naxitamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-370-1mg 1mg 3090
GMP-Bios-ab-370-10mg 10mg 21890
GMP-Bios-ab-370-100mg 100mg 148000
GMP-Bios-ab-370-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-Ganglioside GD2 therapeutic antibody (Pre-made Naxitamab biosimilar,Whole mAb)
INN Name Naxitamab
TargetGanglioside GD2
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesMemorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics
Conditions ApprovedNeuroblastoma
Conditions ActiveOsteosarcoma
Conditions DiscontinuedBreast cancer;Sarcoma;Small cell lung cancer
Development Techna